- Home
- AMSF vs COLL Comparison
AMSF vs COLL Comparison
Compare AMSF & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMSF
- COLL
- Stock Information
- Founded
- AMSF 1985
- COLL 2002
- Country
- AMSF United States
- COLL United States
- Employees
- AMSF N/A
- COLL N/A
- Industry
- AMSF Accident &Health Insurance
- COLL Biotechnology: Pharmaceutical Preparations
- Sector
- AMSF Finance
- COLL Health Care
- Exchange
- AMSF Nasdaq
- COLL Nasdaq
- Market Cap
- AMSF 857.2M
- COLL 958.8M
- IPO Year
- AMSF 2005
- COLL 2015
- Fundamental
- Price
- AMSF $43.00
- COLL $34.94
- Analyst Decision
- AMSF Buy
- COLL Strong Buy
- Analyst Count
- AMSF 2
- COLL 4
- Target Price
- AMSF $57.50
- COLL $44.25
- AVG Volume (30 Days)
- AMSF 73.6K
- COLL 429.5K
- Earning Date
- AMSF 10-22-2025
- COLL 11-06-2025
- Dividend Yield
- AMSF 10.62%
- COLL N/A
- EPS Growth
- AMSF N/A
- COLL N/A
- EPS
- AMSF 2.63
- COLL 1.06
- Revenue
- AMSF $306,470,000.00
- COLL $707,007,000.00
- Revenue This Year
- AMSF $2.98
- COLL $22.23
- Revenue Next Year
- AMSF $5.32
- COLL $2.78
- P/E Ratio
- AMSF $16.33
- COLL $33.24
- Revenue Growth
- AMSF N/A
- COLL 22.61
- 52 Week Low
- AMSF $42.48
- COLL $23.23
- 52 Week High
- AMSF $60.24
- COLL $42.29
- Technical
- Relative Strength Index (RSI)
- AMSF 50.38
- COLL 50.29
- Support Level
- AMSF N/A
- COLL N/A
- Resistance Level
- AMSF $46.53
- COLL $39.12
- Average True Range (ATR)
- AMSF 0.86
- COLL 1.02
- MACD
- AMSF -1.96
- COLL -1.94
- Stochastic Oscillator
- AMSF 89.85
- COLL 87.91
About AMSF AMERISAFE Inc.
AMERISAFE Inc is a specialty provider of workers' compensation insurance focused on small to mid-sized employers engaged in hazardous industries, principally construction, trucking, logging and lumber, agriculture, manufacturing, maritime, and telecommunications. The company generates a majority of its revenue in the form of premiums.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.